Vericel (NASDAQ:VCEL) Upgraded at StockNews.com

StockNews.com upgraded shares of Vericel (NASDAQ:VCEL - Free Report) from a sell rating to a hold rating in a research note released on Tuesday morning.

VCEL has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Vericel in a report on Friday, November 8th. Truist Financial boosted their target price on shares of Vericel from $61.00 to $67.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. BTIG Research upped their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $60.00 price target on shares of Vericel in a report on Tuesday, November 19th. Finally, TD Cowen increased their price objective on Vericel from $55.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, August 27th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Vericel presently has an average rating of "Buy" and a consensus price target of $61.14.

Vericel Trading Up 0.5 %

VCEL traded up $0.27 on Tuesday, hitting $57.31. 102,145 shares of the company's stock were exchanged, compared to its average volume of 425,788. The stock has a fifty day moving average of $52.04 and a two-hundred day moving average of $48.34. Vericel has a twelve month low of $32.31 and a twelve month high of $61.49. The firm has a market cap of $2.83 billion, a PE ratio of 955.33 and a beta of 1.70.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $57.91 million for the quarter, compared to analysts' expectations of $55.32 million. On average, analysts predict that Vericel will post 0.13 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the transaction, the insider now owns 58,371 shares of the company's stock, valued at $3,427,545.12. The trade was a 14.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Paul K. Wotton sold 2,600 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total transaction of $152,672.00. Following the sale, the director now directly owns 27,402 shares of the company's stock, valued at approximately $1,609,045.44. This represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,266 shares of company stock worth $2,090,636 over the last ninety days. Company insiders own 5.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System grew its holdings in shares of Vericel by 3.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 24,500 shares of the biotechnology company's stock worth $1,124,000 after acquiring an additional 900 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Vericel by 3.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 356,434 shares of the biotechnology company's stock worth $16,353,000 after purchasing an additional 12,710 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Vericel by 6.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 420,643 shares of the biotechnology company's stock worth $19,299,000 after buying an additional 25,626 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Vericel by 1.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,031,940 shares of the biotechnology company's stock valued at $47,346,000 after purchasing an additional 10,245 shares during the period. Finally, Rhumbline Advisers increased its stake in Vericel by 1.6% in the 2nd quarter. Rhumbline Advisers now owns 144,572 shares of the biotechnology company's stock valued at $6,633,000 after buying an additional 2,297 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.